{"id":"ckd-843-dose-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Vaginal dryness"},{"rate":null,"effect":"Arthralgia"}]},"_chembl":{"chemblId":"CHEMBL3700878","moleculeType":"Small molecule","molecularWeight":"358.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CKD-843 functions as a SERD by binding to the estrogen receptor with high affinity and promoting its proteasomal degradation, thereby eliminating both ligand-dependent and ligand-independent estrogen receptor signaling. This mechanism differs from selective estrogen receptor modulators (SERMs) by achieving complete receptor elimination rather than partial antagonism. The drug is designed to overcome resistance mechanisms that develop with standard endocrine therapies in hormone receptor-positive breast cancer.","oneSentence":"CKD-843 is a selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, blocking estrogen-dependent signaling in hormone-sensitive cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:01.568Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT06916793","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-04-30","conditions":"Androgenetic Alopecia","enrollment":288},{"nctId":"NCT05587699","phase":"PHASE1","title":"The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-11-15","conditions":"Alopecia","enrollment":41},{"nctId":"NCT04805606","phase":"PHASE1","title":"A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-04-30","conditions":"Alopecia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7357,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CKD-843 dose#1","genericName":"CKD-843 dose#1","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CKD-843 is a treatment being studied for Alopecia and Androgenetic Alopecia in a clinical trial (NCT04805606). The trial is assessing the pharmacokinetic/pharmacodynamic profiles and safety of CKD-843, with multiple intervention arms including CKD-843 A, CKD-843 B, and CKD-843-R.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}